All In Biotech

Drug Trial Radar · NCT05915026

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

A Multicenter, Prospective, Open-label Study to Evaluate the Pharmacokinetics and Safety of Gadoquatrane in Pediatric Participants (From Birth to <18 Years) Undergoing Contrast-enhanced Magnetic Resonance Imaging (CE-MRI)

Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Aug 16, 2023

Primary completion

Sep 18, 2024

Study completion Sep 25, 2024

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to help children under the age of 18 with any known or suspected problems scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI). MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject a contrast agent into a patient's vein to perform a "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve their evaluation. The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd), which is needed for the increase in signal intensity and contrast in MRI. The gadolinium in these contrast agents is caged in a molecule (chelate complex). Researchers are developing new contrast agents with a lower amount of Gd needed per CE-MRI investigation. Gadoquatrane is one of these new contrast agents. It has been tested in several studies previously. The main purpose of this study is to learn how gadoquatrane moves into, through, and out of the body and how safe it is in children. The researchers will measure the amount of gadoquatrane in the blood at different time points after a single injection. The participants will undergo an MRI examination and receive gadoquatrane once at a dose of 0.04 mmol Gd/kg (corresponding to 0.1 mL/kg). It is injected into the participant's vein (also called an intravenous injection) during the MRI examination. Each participant will be in the study for between 8 and 38 days with up to 5 doctor visits, including the screening phase of up to 28 days with no more than 2 visits. Once a participant has received the injection of gadoquatrane, the remaining study duration is 7 (±1) days. At the start or during the study, the doctors and their study team will: * check the weight and height of the participant, * ask for information including age and medical history, * take participants' blood samples, * ask participants and/or their guardians questions about medicines they are taking, * check blood pressure, heart rate and body temperature, * check the area where the participants had the intravenous injection, * do pregnancy tests in girls of childbearing age, * review the MRI scans obtained in the study and decide on the diagnosis * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

Conditions

  • Contrast Enhancement in Magnetic Resonance Imaging
  • Children

Interventions

  • Gadoquatrane (BAY1747846)Drug

    0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve (AUC) of Gadoquatrane After Single AdministrationTime frame: Up to 8 hours post injection
  2. Plasma Clearance Normalized to Body Weight (CL/BW) of Gadoquatrane After Single AdministrationTime frame: Up to 8 hours post injection
  3. Apparent Volume of Distribution at Steady State Normalized to Body Weight (Vss/BW) of Gadoquatrane After Single AdministrationTime frame: Up to 8 hours post injection
  4. Simulation of Plasma Concentration at 10, 20 and 30 Minutes Post-injection (C10, C20 and C30)Time frame: At 10, 20 and 30 minutes post injection

Locations

34 sites in 10 countries. Site status is shown where the registry gives one.

  • Halo Diagnostics - Indian Wells

    Indian Wells, California

  • Children's Mercy Hospital Kansas City - Radiology

    Kansas City, Missouri

  • MUSC University Hospital - Radiology

    Charleston, South Carolina

  • Centro de Diagnostico Enrique Rossi | Departamento de Investigacion Clínica

    Ciudad Autonoma de Buenos Aire, Ciudad Auton. de Buenos Aires, Argentina

  • Sanatorio Allende | Departamento de Investigación Clínica

    Córdoba, Córdoba Province, Argentina

  • Clinica Universitaria Reina Fabiola | Consultorios Externos

    Córdoba, Córdoba Province, Argentina

  • University Multiprofile Hospital for Active Treatment St. Ivan Rilski | Radiology Department

    Sofia, Bulgaria

  • University Hospital for Active Treatment Tsaritsa Joanna - ISUL | Radiology Department

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment Sveti Georgi | Base II - Radiology Department

    Plovdiv, Plovdiv Province, Bulgaria

  • Multiprofile Hospital for Active Treatment Central Onco Hospital | Independent Medical Diagnostic Laboratory Mediscan

    Plovdiv, Plovdiv Province, Bulgaria

  • The Hospital for Sick Children (SickKids)

    Toronto, Ontario, Canada

  • Beijing Children's Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Children's Hospital Zhejiang University School of Med

    Hangzhou, Hangzhou Province, China

  • West China Second University Hospital

    Chengdu, Sichuan, China

  • Fakultní nemocnice Ostrava

    Ostrava - Poruba, Czechia

  • Fakultni nemocnice Plzen - Lochotin

    Pilsen, Czechia

  • Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Pädiatrische Radiologie

    Berlin, Germany

  • Universitätsklinikum Münster - Klinik für Radiologie, Kinderradiologie

    Münster, North Rhine-Westphalia, Germany

  • Universitätsklinikum Leipzig - Institut für Kinderradiologie

    Leipzig, Saxony, Germany

  • Universitätsklinkum Halle (Saale) - Universitätsklinik und Poliklinik für Radiologie, Kinderradiologie

    Halle, Saxony-Anhalt, Germany

  • Universitätsklinikum Jena - Institut für Diagnostische und Interventionelle Radiologie, Kinderradiologie

    Jena, Thuringia, Germany

  • Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital

    Nagoya, Aichi-ken, Japan

  • National Hospital Organization Nagoya Medical Center

    Nagoya, Aichi-ken, Japan

  • Tokai University Hospital

    Isehara, Kanagawa, Japan

  • Kanagawa Children's Medical Center

    Yokohama, Kanagawa, Japan

  • Nara Prefecture General Medical Center

    Nara, Nara, Japan

  • Shizuoka Children's Hospital

    Shizuoka, Shizuoka, Japan

  • Jichi Medical University Hospital

    Shimotsuke, Tochigi, Japan

  • Juntendo University Hospital

    Bunkyo, Tokyo, Japan

  • Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Children's Medical Center

    Fuchū, Tokyo, Japan

  • National Center for Child Health and Development

    Setagaya-ku, Tokyo, Japan

  • Instytut "Pomnik - Centrum Zdrowia Dziecka"

    Warsaw, Poland

  • Karolinska Universitetssjukhuset Solna - Funktion Medicinsk Diagnostik, Barnradiologi

    Stockholm, Stockholm County, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.